Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele… - Leukemia, 2006 - nature.com
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
[引用][C] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E JABBOUR - Leukemia, 2006 - cir.nii.ac.jp
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid
leukemia treated with imatinib mesylate | CiNii Research CiNii 国立情報学研究所 学術情報 …
leukemia treated with imatinib mesylate | CiNii Research CiNii 国立情報学研究所 学術情報 …
[引用][C] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E JABBOUR, H KANTARJIAN, MB RIOS… - …, 2006 - pascal-francis.inist.fr
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid
leukemia treated with imatinib mesylate CNRS Inist Pascal-Francis CNRS Pascal and …
leukemia treated with imatinib mesylate CNRS Inist Pascal-Francis CNRS Pascal and …
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour, H Kantarjian, D Jones, M Talpaz… - …, 2006 - augusta.elsevierpure.com
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
[PDF][PDF] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele… - Leukemia, 2006 - academia.edu
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele… - Leukemia, 2006 - europepmc.org
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
E Jabbour, H Kantarjian, D Jones… - Leukemia …, 2006 - search.ebscohost.com
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
[PDF][PDF] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele… - Leukemia, 2006 - researchgate.net
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour, H Kantarjian, D Jones, M Talpaz… - …, 2006 - ohiostate.elsevierpure.com
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour, H Kantarjian, D Jones, M Talpaz… - …, 2006 - pubmed.ncbi.nlm.nih.gov
Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …
imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing …